Report      Database

    United States Anesthesia Drugs Market & Forecast

    Date: 12 Jun, 2017              Type: Life Science              Pages: 127

    United States Anesthesia Drugs Market & Forecast
    • Electronic Access - Single User License
      $1,800.00
    • CD-ROM Mail Delivery
      $1,900.00
    • Hard-copy Mail Delivery
      $1,950.00
    • Electronic Access - Multi User License
      $2,600.00

    Get Free 10% Customization in this Report

    United States Anesthesia Market is expected to be more than US$ 4 Billion by 2022. This growth is driven by increasing incidence of cardiovascular cases, growing old age population and rising number of urgent surgeries in United States. Private as well as public health insurers also help to boost this market as they consider anesthetic products in their reimbursement policy. 


    General Intravenous Anesthesia is the Leading Segments in the United States ( USA ) Anesthesia Market 

    General intravenous anesthesia is the leading segments in the United States Anesthesia Market.  Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate and Fentanyl are commonly used general intravenous anesthesia in the United States. Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs which hold more than 75 percent combined market share in 2016.


    Major Anesthesia Drug’s Manufacturers are continuously losing their Sales in United Sates 

    In the United States ( USA ) anesthesia drugs market several players are selling their products. Most of the anesthesia drugs sale are in generic form as it is available in the low cost.  However all major drugs manufactures such as AstraZeneca, AbbVie , Endo Healthcare etc. anesthesia products sales are turning down continuously. Only Baxter International anesthesia drugs sales are growing in the United States market.

    United States Anesthesia Drugs Market & Forecast is the 2nd edition report on United States Anesthesia Market published by Renub Research. This 127 page report with 55 Figures and 16 Tables provides a detailed analysis of local and general anesthesia drugs market, health insurers’ anesthesia reimbursement policies, eligibility criteria and reimbursement methods in United States. This report has been studied from 8 viewpoints.

    1.    United Sates Anesthesia Market
    2.    United Sates Anesthesia Drugs Share Analysis
    3.    General Anesthesia Market
    4.    Local Anesthesia Market
    5.    Anesthesia Reimbursement Policy by Health Insurance Companies (Private & Public)
    6.    Major Companies Anesthesia Sales
    7.    United States Anesthesia Market Drivers
    8.    United States Anesthesia Market Challenges

     

    General Intravenous Anesthetic Drugs Market has been further divided into

    1.    Propofol Market (2011 – 2022)
    2.    Benzodiazepines Class (Diazepam and Midazolam) (2011 – 2022)
    3.    Fospropofol Disodium (2011 – 2022)
    4.    Ketamine (2011 – 2022)
    5.    Methohexital Sodium (2011 – 2022)
    6.    Pentobarbital  (2011 – 2022)
    7.    Etomidate (2011 – 2022)
    8.    Fentanyl (2011 – 2022)


    United States Local Anesthetic Market has been further divided into

    1.    Articane (2011 – 2022)
    2.    Bupivacaine (2011 – 2022)
    3.    Lidocaine (2011 – 2022)
    4.    Mepivacaine (2011 – 2022)
    5.    Prilocaine (2011 – 2022)


    Key Players Sales in United States Anesthetic Drugs Market 

    1.    Baxter International Inc (2011 – 2022)
    2.    Endo Health Solutions Inc (2011 – 2022)
    3.    AbbVie (2011 – 2022)
    4.    AstraZeneca (2011 – 2022)


    This report provides the answer of following questions 

    •    Which one is the leading market (Local anesthesia or general Anesthesia) in the United States Anesthesia market?
    •    Which is the leading local anesthesia drug in United States Local Anesthesia Market?
    •    Which is the leading General anesthesia drug in United States General Anesthesia Market?
        What is the market size of each anesthesia drugs during 2011 – 2022?
    •    What is the reimbursement policy on anesthetic services in the United States?
    •    What are the anesthesia drugs sales situations in United States for key anesthesia players?
    •    What is the reimbursements policy in United States for Anesthesia by Private and Public Insurers 

     

    Content from Old Report is given below:

    The user can buy this report in Chapters from Purchase by Chapter section given above

    Anesthesia drugs are used during tests and surgical operations to induce sleep, which prevents pain and discomfort and enables a wide range of medical procedures to be performed. Local Anesthesia and General Anesthesia are the two commonly used types of anesthesia. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation. 

    United States anesthesia drugs market is expected to be more than US$ 3 Billion by 2018. General Intravenous Anesthesia drugs market is dominating the United States anesthesia drugs market. In further classification of General Intravenous Anesthesia Drugs market, Propofol and Benzodiazepines Class (Diazepam and Midazolam) are the top contributors to intravenous anesthetic drugs in the United States anesthesia drugs market. In classification of Local Anesthesia Drugs Market Share Lidocaine holds the maximum market share. From companies analysis part Baxter International Inc, Endo Health Solutions Inc and Abbott Laboratories are three main players, but Others companies also play a major role in United States anesthesia drugs market. 

    Renub Research report titled "United States Anesthesia Drugs Market & Forecast” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 74 page report with 56 Figures and 1 Table provides a complete analysis of local and general anesthesia drugs market in United States. This report has been studied from 2 viewpoints.

    1. General Anesthesia Drugs Market
    2. Local Anesthesia Drugs Market

    General Intravenous Anesthetic Drugs Market has been further divided into

    1. Propofol 
    2. Benzodiazepines Class (Diazepam and Midazolam) 
    3. Fospropofol Disodium 
    4. Ketamine 
    5. Methohexital Sodium
    6. Pentobarbital 
    7. Etomidate 
    8. Fentanyl 

    United States Local Anesthetic Market has been further divided into

    1. Articane 
    2. Bupivacaine 
    3. Lidocaine 
    4. Mepivacaine 
    5. Prilocaine 

    Key Players Profile in United States Anesthetic Drugs Market 

    1. Baxter International Inc 
    2. Endo Health Solutions Inc 
    3. Abbott Laboratories 
    4. AstraZeneca 

    Data Sources 

    This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts. 

    Primary sources include industry surveys and telephonic interviews with industry experts. 

    Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

    1.    Executive Summary

    2.    United States Anesthesia Drugs Market (2011 – 2022)

    3.    United States Anesthesia Drugs Market Share & Forecast (2011 – 2022)
    3.1    United States Anesthesia Drugs Market Share & Forecast by Type (2011 – 2022)

    3.2    United States General Intravenous Anesthesia Drugs Market Share & Forecast (2011 – 2022)

    3.3    United States Local Anesthesia Drugs Market Share & Forecast (2011 – 2022)

    3.4    United States Anesthesia Drugs Market Share & Forecast by Company (2011 – 2022)

    4.    By Type – United States Anesthesia Drugs Market (2011 – 2022)
    4.1    United States General Inhalation Anesthesia Drugs Market (2011 – 2022)

    4.2    United States General Intravenous Anesthesia Drugs Market (2011 – 2022)

    4.3    United States Local Anesthesia Drugs Market (2011 – 2022)

    5.    By Drugs – United States General Intravenous Anesthesia Drugs Market (2011 – 2022)
    5.1    United States Propofol Market (2011 – 2022)

    5.2    United States Benzodiazepines Class (Diazepam and Midazolam) Market (2011 – 2022)

    5.3    United States Fospropofol Disodium Market (2011 – 2022)

    5.4    United States Ketamine Market (2011 – 2022)

    5.5    United States Methohexital Sodium Market (2011 – 2022)

    5.6    United States Pentobarbital Market (2011 – 2022)

    5.7    United States Etomidate Market (2011 – 2022)

    5.8    United States Fentanyl Market (2011 – 2022)

    6.    By Drugs – United States Local Anesthesia Drugs Market (2011 – 2022)
    6.1    United States Articaine Market (2011 – 2022)

    6.2    United States Bupivacaine Market (2011 – 2022)

    6.3    United States Lidocaine Market (2011 – 2022)

    6.4    United States Mepivacaine Market (2011 – 2022)

    6.5    United States Prilocaine Market (2011 – 2022)

    7.    Key Players Profile in United States Anesthesia Drugs Market
    7.1    Baxter International Inc. Anesthesia Drugs Sales & Forecast (2011 – 2022)

    7.2    Endo Health Solutions Inc. Anesthesia Drugs Sales & Forecast (2011 – 2022)

    7.3    AbbVie Anesthesia Drugs Sales & Forecast (2011 – 2022)

    7.4    AstraZeneca Anesthetic Drugs Sales (2009 – 2011)

    8.    United States Anesthesia market Merger & Acquisition (M&A)

    9.    United States Anesthesia Reimbursement Policy - Private Health Insurance Providers
    9.1    Aetna International

    9.2    Coventry Health Care

    9.3    Anthem Blue Cross and Blue Shield

    9.4    Blue Cross and Blue Shield of Texas

    9.5    UnitedHealthcare
    9.5.1    State Exceptions

    10.    United States Anesthesia Reimbursement Policy – Public Health Insurance Providers
    10.1    Medicare

    10.2    MDWise

    11.    United States Anesthesia Drugs Market – Growth Drivers
    11.1    Growing Demand for Anesthesia Service

    11.2    Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States
    11.2.1    Rise in Ageing Population

    12.    United States Anesthesia Drugs Market – Challenges
    12.1    Un-match Anesthesia Providers in United States

    12.2    Shortage of Anesthesia Drugs in United States
     

     

    List of Figures: 

    Figure 2‑1: United States – Anesthesia Drugs Market (Million US$), 2011 – 2016
    Figure 2‑2: United States – Forecast for Anesthesia Drugs Market (Million US$), 2017 – 2022

    Figure 3‑1: United States – Anesthesia Drugs Market Share by Type (Percent), 2011 – 2016
    Figure 3‑2: United States – Forecast for Anesthesia Drugs Market Share by Type (Percent), 2017 – 2022
    Figure 3‑3: United States – General Intravenous Anesthesia Drugs Market Share (Percent), 2011 – 2016
    Figure 3‑4: United States – Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2017 – 2022
    Figure 3‑5: United States – Local Anesthesia Drugs Market Share (Percent), 2011 – 2016
    Figure 3‑6: United States – Forecast for Local Anesthesia Drugs Market Share (Percent), 2017 – 2022
    Figure 3‑7: United States – Anesthesia Drugs Market Share by Company (Percent), 2011 – 2016
    Figure 3‑8: United States – Forecast for Anesthesia Drugs Market Share by Company (Percent), 2017 – 2022

    Figure 4‑1: United States – General Inhalation Anesthesia Drugs Market (Million US$), 2011-2016
    Figure 4‑2: United States – Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2017 – 2022
    Figure 4‑3: United States – General Intravenous Anesthesia Drugs Market (Million US$), 2011 – 2016
    Figure 4‑4: United States – Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2017 – 2022
    Figure 4‑5: United States – Local Anesthesia Drugs Market (Million US$), 2011-2016
    Figure 4‑6: United States – Forecast for Local Anesthesia Drugs Market (Million US$), 2017 – 2022

    Figure 5‑1: United States – Propofol Market (Million US$), 2011 – 2016
    Figure 5‑2: United States – Forecast for Propofol Market (Million US$), 2017 – 2022
    Figure 5‑3: United States – Benzodiazepines Class Market (Million US$), 2011 – 2016
    Figure 5‑4: United States – Forecast for Benzodiazepines Class Market (Million US$), 2017 – 2022
    Figure 5‑5: United States – Fospropofol Disodium Market (Million US$), 2011 – 2016
    Figure 5‑6: United States – Forecast for Fospropofol Disodium Market (Million US$), 2017 – 2022
    Figure 5‑7: United States – Ketamine Market (Million US$), 2011 – 2016
    Figure 5‑8: United States – Forecast for Ketamine Market (Million US$), 2017 – 2022
    Figure 5‑9: United States – Methohexital Sodium Market (Million US$), 2011 – 2016
    Figure 5‑10: United States – Forecast for Methohexital Sodium Market (Million US$), 2017 – 2022
    Figure 5‑11: United States – Pentobarbital Market (Million US$), 2011 – 2016
    Figure 5‑12: United States – Forecast for Pentobarbital Market (Million US$), 2017 – 2022
    Figure 5‑13: United States – Etomidate Market (Million US$), 2011 – 2016
    Figure 5‑14: United States – Forecast for Etomidate Market (Million US$), 2017 – 2022
    Figure 5‑15: United States – Fentanyl Market (Million US$), 2011 – 2016
    Figure 5‑16: United States – Forecast for Fentanyl Market (Million US$), 2017 – 2022

    Figure 6‑1: United States – Articaine Market (Million US$), 2011-2016
    Figure 6‑2: United States – Forecast for Articane Market (Million US$), 2017 – 2022
    Figure 6‑3: United States – Bupivacaine Market (Million US$), 2011-2016
    Figure 6‑4: United States – Forecast for Bupivacaine Market (Million US$), 2017 – 2022
    Figure 6‑5: United States – Lidocaine Market (Million US$), 2011-2016
    Figure 6‑6: United States – Forecast for Lidocaine Market (Million US$), 2017 – 2022
    Figure 6‑7: United States – Mepivacaine Market (Million US$), 2011-2016
    Figure 6‑8: United States – Forecast for Mepivacaine Market (Million US$), 2017 – 2022
    Figure 6‑9: United States – Prilocaine Market (Million US$), 2011-2016
    Figure 6‑10: United States – Forecast for Prilocaine Market (Million US$), 2017 – 2022

    Figure 7‑1: United States – Baxter International Anesthesia Drugs Sales (Million US$), 2011-2016
    Figure 7‑2: United States – Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2017 – 2022
    Figure 7‑3: United States – Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2011-2016
    Figure 7‑4: United States – Forecast for Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2017 – 2022
    Figure 7‑5: United States – AbbVie Anesthesia Drugs Sales (Million US$), 2011 - 2016
    Figure 7‑6: United States – Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2017 – 2022
    Figure 7‑7: United States – AstraZeneca Anesthesia Drugs Sales (Million US$), 2009 – 2011

    Figure 11‑1: United States – Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
    Figure 11‑3: United States – Ageing Population by Age Group (Thousand), 2012 – 2016

    Figure 12‑1: United States – By Region Availability of Anesthesia Specialists (Percent), 2010
    Figure 12‑2: United States – By States Availability of Anesthesia Specialists (Percent), 2010
    Figure 12‑3: United States – Drugs Shortage (Number), 2001-2015
    Figure 12‑4: United States – Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012

     

    List of Tables:

    Table 8‑1: United States – Anesthesia Market Merger & Acquisitions (M&A), Jan 2016 – March 2017

    Table 9‑1: Coventry Health Care - Anesthesia Modifiers, 2016
    Table 9‑2: Blue Cross and Blue Shield of Texas - Physical Status Modifiers, 2017
    Table 9‑3: Blue Cross and Blue Shield of Texas - Qualifying Circumstances, 2017
    Table 9‑4: Blue Cross and Blue Shield of Texas - Modifier Information Billed by an Anesthesiologist, 2017
    Table 9‑5: Blue Cross and Blue Shield of Texas - Modifier Information Billed by a CRNA, 2017
    Table 9‑6: Blue Cross and Blue Shield of Texas - Anesthesia Modifier Reimbursement
    Table 9‑7: UnitedHealthcare Community – Modifiers, 2017

    Table 10‑1: Medicare - Reimbursement Formulas
    Table 10‑2: Medicare - General and Monitored Anesthesia Care
    Table 10‑3: Medicare - Anesthesia Modifiers, 2017
    Table 10‑4: MDwise –Type of Service & PA Requirement
    Table 10‑5: MDwise - Anesthesia Time Table, 2017
    Table 10‑6: MDwise - Qualifying Circumstances, 2017
    Table 10‑7: MDwise - Status Modifiers, 2017

    Table 11‑1: United States – Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
     

    • Description
      Price
    • Chapter 1 & 2     Pages : 3
      $250
    • Chapter 3     Pages : 9
      $375
    • Chapter 4     Pages : 6
      $300
    • Chapter 5     Pages : 15
      $350
    • Chapter 6     Pages : 8
      $300
    • Chapter 7     Pages : 9
      $300
    • Chapter 8     Pages : 4
      $200
    • Chapter 9     Pages : 8
      $200

    Related Products